Key drivers in the evolution of specimen collection solutions, Nicholas Lorenzo, MD, MHCM, CPE, FAAPL, and Michael C. Wadman, MD, FACEP, recently shared insights in an article for Today’s Clinical Lab on why highly sensitive nasal lavage could soon replace nasal swabs as the frontline sampling solution in clinical settings — especially during future flu, RSV or COVID-19 outbreaks.
While nasal swabs became the default during the COVID-19 pandemic, they were never the gold standard. Educating healthcare and laboratory leaders on what to look for in an effective sampling method, the co-authors noted the drawbacks of nasal swabs compared to the groundbreaking advantages of evolved nasal lavage kits, like MicroWash, for providers, patients and labs.
The MicroWash offers a longer shelf life, simple lab integration, higher public acceptance rates, CPT coding reimbursement and increased safety, among other differentiators — such as 49% greater sample sensitivity than the swab. This highlights why reimagined nasal lavage is a cutting-edge method raising specimen collection standards for current URI management and for future outbreaks.
Dr. Lorenzo is a seasoned medical executive with a diverse background in neurology, healthcare management and entrepreneurship. He currently serves as the Chairman, Chief Executive Officer and President of MicroWash, and the Founder and CEO of PHLT Consulting, a national healthcare consulting firm.
Dr. Wadman is a veteran emergency physician who also holds tenured professor and endowed chair positions at University of Nebraska Medical Center, one of the nation’s leading healthcare institutions for pandemic response. As Chief Medical Officer, his emergency medicine and infectious disease experience drives medical excellence in device development.
Read the full article and discover the data behind MicroWash.
